B. K. BLACKBURN

Development of a humanized disulfide-stabilized anti-p185HER2 Fv-beta-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug.

Maria Luı́sa Rodrigues, Leonard G. Presta, Claire E. Kotts et al. · PubMed · 1995 · 78 citations

Immunology, Antimicrobial Chemotherapy, Cephalosporin Doxorubicin Prodrug +20

Neuroprotection achieved with a novel proteasome inhibitor which blocks NF-κB activation

Alastair M. Buchan, H Li, B. K. BLACKBURN · Neuroreport · 2000 · 49 citations

Immunology, Cell Death, Cerebrovascular Disease +29

2-SUBSTITUTED PI SYSTEM DERIVATIVES OF ADENOSINE THAT ARE CORONARY VASODILATORS ACTING VIA THE A_2AADENOSINE RECEPTOR

Jeff Zablocki, Venkata P. Palle, B. K. BLACKBURN et al. · Nucleosides Nucleotides & Nucleic Acids · 2001 · 32 citations

Molecular Pharmacology, Molecular Physiology, Biochemistry +13

Pharmacokinetics, pharmacodynamics and tolerability of a potent, non-peptidic, GP IIb/IIIa receptor antagonist following multiple oral administrations of a prodrug form.

Canio J. Refino, Nishit B. Modi, Sherron Bullens et al. · PubMed · 1998 · 27 citations

Molecular Pharmacology, Thrombosis, Prodrug Form +15